{"id":391616,"date":"2014-06-26T00:00:00","date_gmt":"2014-06-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbaspd1714-biopharma-rheumatoid-arthritis-decisionbase-us-eu5-2014\/"},"modified":"2026-03-31T09:05:06","modified_gmt":"2026-03-31T09:05:06","slug":"dbaspd1714-biopharma-rheumatoid-arthritis-decisionbase-us-eu5-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbaspd1714-biopharma-rheumatoid-arthritis-decisionbase-us-eu5-2014\/","title":{"rendered":"Rheumatoid Arthritis | DecisionBase | US\/EU5 | 2014"},"content":{"rendered":"<p><em>With the High Efficacy Bar That TNF-Alpha Inhibitors Set, What Are the Remaining Areas of Opportunities for Emerging Therapies to Fill?<\/em><\/p>\n<p>Nine biologics are approved to treat rheumatoid arthritis (RA), along with an oral kinase inhibitor (tofacitinib [Pfizer\/Takeda\u2019s Xeljanz]). Given rheumatologists\u2019 long-standing familiarity with the safety and efficacy profiles of the TNF-\u03b1 inhibitors, the first of which was approved in 1998, and, increasingly, of abatacept (Bristol-Myers Squibb\/Ono Pharmaceutical\u2019s Orencia), rituximab (Biogen Idec\/Roche\/Chugai\/Zenyaku Kogyo\u2019s Rituxan, Roche\u2019s MabThera), and tocilizumab (Roche\/Chugai\u2019s RoActemra\/Actemra), new agents face challenges in gaining uptake. To help drug developers negotiate the formidable barriers to uptake in this market, this report identifies attributes with the greatest power to sway rheumatologists\u2019 prescribing decisions and the gaps in efficacy and safety of select current and emerging therapies.<\/p>\n","protected":false},"template":"","class_list":["post-391616","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391616\/revisions"}],"predecessor-version":[{"id":394739,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391616\/revisions\/394739"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}